Latest News
Tuesday preview: US Q2 unit labour costs, IHG in focus
The market spotlight on Tuesday will be on quarterly labour productivity and unit labour cost data in the US covering the three months to June.
Europe close: Stocks up in quiet start to the week
European shares began the week on the front foot on a relatively quiet day for economic reports and company earnings.
London close: Stocks rise as investors shrug off central bank risks
London stocks managed to close in positive territory on Monday, buoyed by a rise at the open for US markets, and after some mixed trade data out of China.
Broker tips: Hargreaves Lansdown, Touchstone Exploration, Legal & General
Analysts at Barclays took a fresh look at financial services giant Hargreaves Lansdown following the release of the group's full-year results last week.
FTSE 250 movers: PageGroup slumps on cautious outlook
The FTSE 250 was up 0. 61% at 20,173. 78 at 1536 BST.
US open: Stocks trade higher ahead of CPI reading
Wall Street stocks were in the green early on Monday ahead of a key inflation report scheduled for later in the week.
Ryanair threatens legal action against Hungary over 'unjustfied' fine
Low-cost airline Ryanair said it would take the Hungarian government to court after it was fined for passing an "unjustified" windfall tax onto customers.
BioNTech misses Q2 sales forecasts as it prepares possible launch of new Covid vaccines
BioNTech reported a larger-than-expected drop in quarterly revenues, even as it progressed on the roll-out of new Covid-19 vaccines and its pipeline of potential cancer treatments.
FTSE 100 movers: Hargreaves Lansdown rallies; Phoenix hit by downgrade
London’s FTSE 100 was up 0. 9% at 7,505. 02 in afternoon trade on Monday.
Risk/reward for equities 'not all bad' heading into year-end, says JPMorgan
JPMorgan Cazenove said on Monday that the risk/reward for equities is "not all bad" as we head into year-end.
Palantir lowers full-year guidance, pulls forecast for medium-term growth
Shares of Palantir reeled after the data analytics outfit guided lower for full-year sales and profits.
Director dealings: Purplebricks shares rise after CEO purchase
Online estate agency Purplebricks saw its shares surge on Monday, as it disclosed three share purchases worth almost £0. 1m made by its chief executive officer.
Good Energy investment Zap-Map completes £9m series-A round
Renewable electricity supplier Good Energy announced on Monday that electric vehicle charging point mapping service Zap-Map has completed a £9m series-A fundraising, valuing Zap-Map at a £26. 3m post-money equity value.
WH Smith secures pension de-risking deal with Standard Life
WH Smith's pension fund on Monday said it had insured the benefits of all its pension members in a deal with Standard Life.
Canaccord Genuity nudges up target price on Touchstone Exploration
Analysts at Canaccord Genuity slightly raised their target price on exploration and production firm Touchstone Exploration from 190. 0p to 200. 0p on Monday after the group secured environmental approvals for its Cascadura development.
Solid State completes acquisition of LA-based Custom Power
Computing, power and communications value-added component supplier Solid State has completed the acquisition of Custom Power, it announced on Monday.
Anglo Asian Mining joins Libero Copper's private placement
Azerbaijan-focussed gold, copper and silver producer Anglo Asian Mining has made a further investment in Libero Copper & Gold Corporation, it announced on Monday.
Tertiary Minerals sells Finnish royalties to Canada's Aurion
Tertiary Minerals has accepted a binding offer from Aurion Resources for the purchase of its royalty interests in the Kaaresselkä and Kiekerömaa gold projects in Finland, it announced on Monday.
Egdon, Union Jack confirm appeal to Lincolnshire council planning refusal
Egdon Resources and Union Jack Oil both told shareholders on Monday that an appeal against a refusal by the Lincolnshire County Council had been submitted.
Pfizer to buy Global Blood Therapeutics in $5.4bn deal
Pfizer has agreed to buy biopharmaceutical group Global Blood Therapeutics for $5. 4bn in cash.